Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevasemten in Becker Muscular Dystrophy
NCT05291091Phase 2Completed
- Start
- Nov 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of sevasemten in Becker muscular dystrophy (BMD) (5 cohorts). Primary endpoints: Number of treatment emergent adverse events at 18 months, Severity of treatment emergent adverse events at 18 months and 2 more. Started Nov 2022; status: completed.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT05291091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291091.